Hormonal
Metabolic dysfunction-associated steatotic liver disease (MASLD) is bidirectionally associated with the development and progression of cardiovascular, renal, and metabolic disorders, acting as both a driver and consequence of systemic cardiometabolic dysfunction.
If you have fatty liver (MASLD), it is not just a liver issue; it significantly increases your risk for heart disease, kidney disease, and diabetes. You need to manage your metabolic health (weight, blood sugar, blood pressure) comprehensively to protect your heart and kidneys, not just your liver.
MASLD, the hepatic manifestation of metabolic dysregulation, is both a driver and a consequence of metabolic dysfunction. Its progression to metabolic dysfunction-associated steatohepatitis (MASH) is closely intertwined with insulin resistance and obesity, creating a bidirectional relationship that exacerbates the development and progression of atherosclerosis, HF, and CKD
Why this rating
The paper cites specific hazard ratios and odds ratios from guidelines (EASL-EASD-EASO) linking MASLD to increased mortality and morbidity, indicating strong observational evidence.
Source
From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework
Nikolaos Theodorakis et al. · Biomolecules · 2025
DOI 10.3390/biom15020213
More from this paper
- Excess adiposity, particularly visceral fat, is the central driver of the Cardiovascular-Renal-Hepatic-Metabolic (CRHM) syndrome, leading to insulin resistance, inflammation, and multi-organ dysfunction.Strong
- SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone demonstrate benefits across multiple cardiometabolic conditions, improving clinical outcomes in patients with MASLD, CKD, and CVD.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →